Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: SOCHANIK
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/2

Tytuł oryginału: Various cationic carriers for in vitro transfection of tumor and endothelial cell lines.
Autorzy: Zemlińska Barbara, Sochanik Aleksander, Missol-Kolka Ewa, Szala Stanisław
Źródło: Acta Bioch. Pol. 2002: 49 (1) s.285-290, il., tab., bibliogr. 21 poz.
Sygnatura GBL: 303,116

Hasła klasyfikacyjne GBL:
  • genetyka
  • onkologia

    Typ dokumentu:
  • praca doświadczalna
  • komunikat
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • zwierzęta
  • myszy
  • in vitro

    Streszczenie angielskie: We compared the efficiency of in vitro DNA transfer into selected tumor and endothelial cell lines using complexes of plasmid DNA and cationic carriers: DDAB/DOPE, DC-Chol/DOPE, Art-Chol/DOPE, Gly-Chol/DOPE, Arg-Gly-Chol/DOPE, BGTC/DOPE, and PEI. The best carriers for transfecting the majority of tested cells lines at optimized carrier-to-DNA weight ratios were PEI and BGTC/DOPE.

    2/2

    Tytuł oryginału: Antiangiogenic gene therapy in inhibition of metastasis.
    Autorzy: Szala Stanisław, Szary Jarosław, Cichoń Tomasz, Sochanik Aleksander
    Źródło: Acta Bioch. Pol. 2002: 49 (2) s.313-321, il., tab., bibliogr. s. 319-321 - 37 Spotkanie Polskiego Towarzystwa Biochemicznego Toruń 10-14.09. 2001
    Sygnatura GBL: 303,116

    Hasła klasyfikacyjne GBL:
  • genetyka
  • onkologia

    Typ dokumentu:
  • praca związana ze zjazdem
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta

    Streszczenie angielskie: This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Certain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream rpoteins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these proteins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be controlled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiotics, such as tetracycline derivatives, or steroid hormones.

    stosując format: